SCHEMBL30055372

SCHEMBL30055372

Nc1ncnc2scc(-c3ccc(NC(=O)Nc4cc(C(F)(F)F)ccc4F)cc3)c12

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KIT P10721 10/20 1.00
FLT1 P17948 9/20 1.00
FLT3 P36888 9/20 1.00
CSF1R P07333 8/20 1.00
LCK P06239 8/20 1.00
FGFR1 P11362 6/20 1.00
AURKA O14965 6/20 1.00
ABL1 P00519 6/20 1.00
FYN P06241 6/20 1.00
LYN P07948 6/20 1.00
BLK P51451 6/20 1.00
GSK3B P49841 5/20 1.00
FGFR3 P22607 5/20 1.00
PLK4 O00444 5/20 1.00
NTRK1 P04629 5/20 1.00
RPS6KB1 P23443 5/20 1.00
MARK3 P27448 5/20 1.00
RPS6KA3 P51812 5/20 1.00
NEK2 P51955 5/20 1.00
LIMK1 P53667 5/20 1.00

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL546436 1.00 KIT (1.00) KITFLT1FLT3CSF1RLCK
Bromide SCHEMBL5436521 0.99 KIT (0.98) KITFLT1FLT3CSF1RLCK
Hydrochloric Acid SCHEMBL4301600 0.99 KIT (0.98) KITFLT1FLT3CSF1RLCK
Alcohol SCHEMBL3238965 0.97 FLT1 (0.93) KITFLT1FLT3CSF1RLCK
SCHEMBL3567468 0.91 KIT (0.83) KITFLT1FLT3CSF1RLCK
SCHEMBL4473254 0.91 KIT (0.83) KITFLT1FLT3CSF1RLCK
SCHEMBL4487735 0.90 KIT (0.82) KITFLT1FLT3CSF1RLCK
SCHEMBL4486498 0.90 KIT (0.82) KITFLT1FLT3CSF1RLCK
SCHEMBL4478648 0.89 FLT1 (0.79) KITFLT1FLT3CSF1RLCK
SCHEMBL4478281 0.88 KIT (0.78) KITFLT1FLT3CSF1RLCK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4663249-A2 DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS Yale University, Inc. (US) 2025-12-17 EP disclosed
EP-4186501-B1 DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS YALE UNIV INC (US) 2025-07-30 EP disclosed
EP-4334305-A1 WDR5 INHIBITORS AND MODULATORS Vanderbilt University (US) 2024-03-13 EP disclosed
EP-4186501-A1 DRUG THERAPY TO INHIBIT CHEMOTHERAPY-INDUCED ADVERSE EFFECTS AND RELATED PHARMACEUTICAL COMPOSITIONS, DIAGNOSTICS, SCREENING TECHNIQUES AND KITS Yale University, Inc. (US) 2023-05-31 EP disclosed
WO-2022236101-A1 WDR5 INHIBITORS AND MODULATORS VANDERBILT UNIVERSITY (US) 2022-11-10 WO disclosed
WO-2022216717-A1 CITRON KINASE INHIBITORS THE CLEVELAND CLINIC FOUNDATION (US) 2022-10-13 WO disclosed